Diffuse aggressive B-cell lymphomas.
Diffuse aggressive B-cell lymphomas comprise a relatively common and increasingly diverse group of neoplasms. Newer modalities including gene expression profiling and an increasing panel of immunohistochemical markers have contributed to greater accuracy in defining these entities. Attention is paid not only to the neoplastic cells but also to the cellular and stromal milieu in which they proliferate. These distinctions may have therapeutic implications as well, with improved outcome related to newer and sometimes targeted therapies. At the same time there is increasing understanding of the overlap, which occurs in the grey zone between diffuse large B-cell lymphoma and Burkitt lymphoma as well as between diffuse large B-cell lymphoma and Hodgkin lymphoma. This review aims to provide practical insights in the correct identification and differential diagnosis of these lymphomas, with emphasis on the changes that have occurred with the publication of the 2008 World Health Organization updated classification.
Said
Jonathan
J
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. jsaid@mednet.ucla.edu
D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D001853:Bone Marrow / Q000473:pathology; D001856:Bone Marrow Examination; D002051:Burkitt Lymphoma / Q000175:diagnosis*; D003937:Diagnosis, Differential; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006689:Hodgkin Disease / Q000175:diagnosis*; D006801:Humans; D007150:Immunohistochemistry; D016403:Lymphoma, Large B-Cell, Diffuse / Q000737:chemistry / Q000145:classification / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000821:virology; D011237:Predictive Value of Tests; D017154:Stromal Cells / Q000473:pathology; D014944:World Health Organization
D014408:Biomarkers, Tumor